Trial · NCT06433050
Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy
NCT06433050, Early phase 1, Active not recruiting, University of Pennsylvania
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy. Trials, record NCT06433050. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06433050
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy
- NCT number
- NCT06433050
- Status
- Active not recruiting
- Phases
- Early phase 1
- Enrollment
- 26 participants, estimated
- Lead sponsor
- University of Pennsylvania
- Conditions
- Hypertrophic Cardiomyopathy Without Obstruction
- Interventions
- Sotagliflozin
- First posted
- 2024-05-29
- Last updated
- 2026-11-09
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with treatment-related adverse events | Through study completion, 28 weeks | Adverse event reporting |
| Primary | Intracavitary obstruction | Through study completion, 28 weeks | Intracavitary left ventricular pressure gradient in mmHg |
| Primary | Cardiac rhythm | Through study completion, 28 weeks | New occurrence of cardiac arrhythmia measured by ambulatory monitoring |
| Primary | Maximal exercise capacity | Through study completion, 28 weeks | Peak oxygen consumption in mL/min |
| Primary | Submaximal exercise capacity | Through study completion, 28 weeks | Stroke volume augmentation at exercise steady state in mL/min |
| Secondary | Systolic function | Through study completion, 28 weeks | Left ventricular ejection fraction in % measured by echocardiography |
| Secondary | Contractility | Through study completion, 28 weeks | Global longitudinal strain in % measured by echocardiography |
| Secondary | Diastolic function | Through study completion, 28 weeks | E/E' ratio measured by echocardiography |
| Secondary | Left ventricular hypertrophy | Through study completion, 28 weeks | Maximal left ventricular wall thickness in mm by echocardiography |
| Secondary | Symptom scores | Through study completion, 28 weeks | Kansas City Living with Heart Failure (KCCQ) Clinical Summary Score, scale 0-100 with lower scores being worse |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R61HL164376 | SGLT-inhibitors in patients with hypertrophic cardiomyopathy | DAY, SHARLENE M | UNIVERSITY OF PENNSYLVANIA | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2023 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06433050
GET https://conductscience.org/api/trials/v1/NCT06433050/registered